MCID: ADL017
MIFTS: 58

Adult T-Cell Leukemia

Categories: Rare diseases, Cancer diseases, Skin diseases, Blood diseases, Immune diseases

Aliases & Classifications for Adult T-Cell Leukemia

MalaCards integrated aliases for Adult T-Cell Leukemia:

Name: Adult T-Cell Leukemia 38 12 14
Adult T-Cell Leukemia/lymphoma 12 50 56
Atll 50 56
Adult T-Cell Leukaemia/lymphoma 50
Leukemia-Lymphoma, Adult T-Cell 42
T Cell Leukemia Lymphoma Adult 52
Adult T-Cell Lymphoma/leukemia 69
Adult T-Cell Leukaemia 50
Adult T-Cell Lymphoma 50
Leukemia, T-Cell 69

Characteristics:

Orphanet epidemiological data:

56
adult t-cell leukemia/lymphoma
Inheritance: Multigenic/multifactorial,Not applicable; Age of onset: Adult;

Classifications:



External Ids:

Disease Ontology 12 DOID:0050523
ICD10 33 C91.5 C91.50
MeSH 42 D015459
NCIt 47 C3184
Orphanet 56 ORPHA86875
MESH via Orphanet 43 D015459
UMLS via Orphanet 70 C0023493
ICD10 via Orphanet 34 C91.5
UMLS 69 C0023493

Summaries for Adult T-Cell Leukemia

NIH Rare Diseases : 50 adult t-cell leukemia/lymphoma (atl) is is a rare and aggressive t-cell lymphoma that is linked to infection by the human t-cell lymphotropic virus 1 (htlv-1). the exact mechanism by which htlv-i infection causes the atl is unknown. the clinical features of atl include generalized swelling of the lymph nodes (lymphadenopathy), increased liver and spleen size (hepatosplenomegaly), immunosuppression, high levels of calcium in the blood, lytic bone lesions (spots that appear as “holes” on a standard bone x-ray), and skin lesions.  there are four basic clinical variants of atl: acute (60% of cases), lymphomatous (20 % of cases), chronic (10% of cases) and smoldering (10% of cases). the best treatment for these patients is unclear and patients should be enrolled in clinical trials whenever possible. medication may include chop (cyclophosphamide, doxorubicin, vincristine and prednisone) or epoch (etoposide, vincristine, doxorubicin, cyclophosphamide and prednisone). in some patients, a bone marrow transplant may be recommended. last updated: 9/13/2016

MalaCards based summary : Adult T-Cell Leukemia, also known as adult t-cell leukemia/lymphoma, is related to myelitis and human t-cell leukemia virus type 1. An important gene associated with Adult T-Cell Leukemia is PMAIP1 (Phorbol-12-Myristate-13-Acetate-Induced Protein 1), and among its related pathways/superpathways are ERK Signaling and Apoptosis Modulation and Signaling. The drugs Cyclophosphamide and Dexamethasone have been mentioned in the context of this disorder. Affiliated tissues include t cells, bone and bone marrow, and related phenotypes are Synthetic lethal with MLN4924 (a NAE inhibitor) and endocrine/exocrine gland

Disease Ontology : 12 A T-cell leukemia that results_in abnormal increase of lymphocytes, derives from T-cells, has material basis in Human T-lymphotropic virus 1, which is transmitted_by sexual contact, transmitted_by contaminated needles used by intravenous-drug users, and transmitted_by breast feeding. The infection results_in_formation_of skin lesions.

Related Diseases for Adult T-Cell Leukemia

Diseases in the T-Cell Leukemia family:

Adult T-Cell Leukemia Acute T Cell Leukemia
Human T-Cell Leukemia Virus Type 1 Human T-Cell Leukemia Virus Type 2
Human T-Cell Leukemia Virus Type 3 Leukemia, B-Cell, Chronic
Leukemia, T-Cell, Chronic

Diseases related to Adult T-Cell Leukemia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 139)
id Related Disease Score Top Affiliating Genes
1 myelitis 30.3 CNTN2 IL2 IL2RA
2 human t-cell leukemia virus type 1 11.3
3 tropical spastic paraparesis 11.3
4 leukemia 11.2
5 t-cell leukemia 11.2
6 lymphoma 11.0
7 myelopathy, htlv-1-associated 11.0
8 lymphoid leukemia 11.0
9 retrovirus-associated myelopathy 11.0
10 cervical adenoid cystic carcinoma 10.7 CDKN2A TP53
11 plagiocephaly and x-linked mental retardation 10.7 CD7 TNFRSF8
12 barbiturate dependence 10.6 CDKN2A IL2 IL2RA
13 split hand split foot nystagmus 10.6 CDKN2A TP53
14 piussan lenaerts mathieu syndrome 10.6 CD7 TNFRSF8
15 embryonal rhabdomyosarcoma 10.5 CDKN2A IL2 TP53
16 childhood cerebellar astrocytic neoplasm 10.5 BCL11B IL2 IL2RA
17 post-surgical hypoinsulinemia 10.5 CDKN2A IL2 TP53
18 pancreatic somatostatinoma 10.5 CDKN2A FOXP3 TP53
19 acral lentiginous melanoma 10.5 IL2 IL2RA TP53
20 unilateral retinoblastoma 10.4 CCND2 CDKN2A TP53
21 leiomyoma cutis 10.4 CDKN2A TP53
22 hemolytic anemia due to triosephosphate isomerase deficiency 10.4 BCL2L1 FOXP3 IL2RA
23 pharynx cancer 10.4 CCND2 CDKN2A TP53
24 penile disease 10.4 CD7 CDKN2A TNFRSF8
25 siderosis 10.4 FAS FOXP3
26 pyridoxine-responsive sideroblastic anemia 10.4 IL2 IL2RA TNFRSF8
27 hematopoietic stem cell transplantation 10.4
28 brown-vialetto-van laere syndrome 10.4 CDKN2A IL2 TP53
29 marinesco-sjogren-like syndrome 10.3 TNFRSF8 TP53
30 duodenum cancer 10.3 CDKN2A FAS TP53
31 acute t cell leukemia 10.3
32 acute myocardial infarction 10.3 CDKN2A IL2 TP53
33 malignant hyperthermia 10.2 CD7 IL2 IL2RA TNFRSF8
34 spastic paraparesis 10.2
35 spasticity 10.2
36 epstein-barr virus, susceptibility to chronic infection by 10.2 CD7 IL2 IL2RA TNFRSF8
37 gallbladder cancer 10.2 BCL2L1 CDKN2A TP53
38 childhood testicular mixed germ cell tumor 10.2 FAS FOXP3 IL2 IL2RA
39 hemolytic anemia 10.1 IL2 IL2RA PTHLH TNFRSF8
40 pneumonia 10.1
41 alport syndrome-intellectual disability-midface hypoplasia-elliptocytosis syndrome 10.1 FAS IL2RA
42 congenital symblepharon 10.1 FAS FOXP3 IL2 IL2RA
43 methylmalonic acidemia cb1a type 10.1 FAS IL2 IL2RA
44 anal squamous cell carcinoma 10.1 CDKN2A TP53
45 mycosis fungoides 10.1
46 peripheral t-cell lymphoma 10.1
47 scabies 10.1
48 hartnup disorder 10.1 BCL2L1 CADM1 CDKN2A TP53
49 endotheliitis 10.0
50 dermatitis 10.0

Graphical network of the top 20 diseases related to Adult T-Cell Leukemia:



Diseases related to Adult T-Cell Leukemia

Symptoms & Phenotypes for Adult T-Cell Leukemia

GenomeRNAi Phenotypes related to Adult T-Cell Leukemia according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.83 BCL2L1 TP53 CDKN2A EPC1 FAS IL2
2 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.83 TP53 CDKN2A EPC1 FAS IL2 IL2RA

MGI Mouse Phenotypes related to Adult T-Cell Leukemia:

44 (show all 14)
id Description MGI Source Accession Score Top Affiliating Genes
1 endocrine/exocrine gland MP:0005379 10.37 BCL11B BCL2L1 CADM1 CCND2 CD7 CDKN2A
2 hematopoietic system MP:0005397 10.36 CADM1 CCND2 CD7 CDKN2A EPC1 FAS
3 behavior/neurological MP:0005386 10.35 BCL11B BCL2L1 CADM1 CCND2 CDKN2A CNTN2
4 immune system MP:0005387 10.31 TNFRSF8 TP53 BCL11B BCL2L1 CADM1 CCND2
5 growth/size/body region MP:0005378 10.29 BCL11B BCL2L1 CADM1 CDKN2A EPC1 FAS
6 cellular MP:0005384 10.26 BCL11B BCL2L1 CADM1 CDKN2A FAS FOXP3
7 homeostasis/metabolism MP:0005376 10.25 BCL11B BCL2L1 CCND2 CDKN2A EPC1 FAS
8 digestive/alimentary MP:0005381 10.11 TP53 CDKN2A FAS FOXP3 IL2 IL2RA
9 mortality/aging MP:0010768 10.1 JUND PRDM16 PTHLH TP53 TXN BCL11B
10 integument MP:0010771 9.97 FOXP3 PRDM16 PTHLH TP53 BCL11B BCL2L1
11 liver/biliary system MP:0005370 9.92 CCND2 CDKN2A FAS FOXP3 IL2 JUND
12 reproductive system MP:0005389 9.85 BCL2L1 CADM1 CCND2 CDKN2A FAS FOXP3
13 respiratory system MP:0005388 9.61 FOXP3 IL2 IL2RA JUND PRDM16 PTHLH
14 vision/eye MP:0005391 9.32 TP53 BCL11B CCND2 CDKN2A FAS FOXP3

Drugs & Therapeutics for Adult T-Cell Leukemia

Drugs for Adult T-Cell Leukemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 434)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 50-18-0, 6055-19-2 2907
2
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 50-02-2 5743
3
Epirubicin Approved Phase 4,Phase 2 56420-45-2 41867
4
Etoposide Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 33419-42-0 36462
5
Gemcitabine Approved Phase 4,Phase 2,Phase 1 95058-81-4 60750
6
Ifosfamide Approved Phase 4,Phase 3,Phase 2,Phase 1 3778-73-2 3690
7
Prednisone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 53-03-2 5865
8
Vincristine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 2068-78-2, 57-22-7 5978
9
Daclizumab Approved, Investigational Phase 4,Phase 1,Phase 2 152923-56-3
10
Cisplatin Approved Phase 4,Phase 2,Phase 1 15663-27-1 84093 441203 2767
11
Bupivacaine Approved, Investigational Phase 4,Phase 1,Phase 2 2180-92-9, 38396-39-3 2474
12
Ropivacaine Approved Phase 4 84057-95-4 71273 175805
13 Antibodies Phase 4,Phase 3,Phase 1,Phase 2
14 Immunoglobulins Phase 4,Phase 3,Phase 1,Phase 2
15 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
16 Alkylating Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
17 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
18 Antibiotics, Antitubercular Phase 4,Phase 3,Phase 2,Phase 1
19 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Phase 1
20 Antimitotic Agents Phase 4,Phase 3,Phase 2,Phase 1
21 Antineoplastic Agents, Hormonal Phase 4,Phase 3,Phase 2,Phase 1
22 Antineoplastic Agents, Phytogenic Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
23 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
24 BB 1101 Phase 4,Phase 3,Phase 2,Phase 1
25 Dexamethasone acetate Phase 4,Phase 3,Phase 2,Phase 1 1177-87-3
26 Etoposide phosphate Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
27 glucocorticoids Phase 4,Phase 3,Phase 2,Phase 1
28 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1
29 Hormones Phase 4,Phase 3,Phase 2,Phase 1
30 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1
31 Isophosphamide mustard Phase 4,Phase 3,Phase 2,Phase 1
32 Topoisomerase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
33 Anesthetics Phase 4,Phase 3,Phase 2,Phase 1
34 Central Nervous System Depressants Phase 4,Phase 3,Phase 2,Phase 1
35 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1
36 Anesthetics, Local Phase 4,Phase 2,Phase 1
37 Calamus Nutraceutical Phase 4
38
Cefepime Approved Phase 3 88040-23-7 5479537
39
Levofloxacin Approved, Investigational Phase 3 100986-85-4 149096
40
Ofloxacin Approved Phase 3 82419-36-1 4583
41
Amoxicillin Approved, Vet_approved Phase 3 26787-78-0 33613 2171
42
Ciprofloxacin Approved, Investigational Phase 3 85721-33-1 2764
43
Ketamine Approved, Vet_approved Phase 3 6740-88-1 3821
44
Doxorubicin Approved, Investigational Phase 3,Phase 2,Phase 1 23214-92-8 31703
45
Lenograstim Approved Phase 3,Phase 2,Phase 1 135968-09-1
46
rituximab Approved Phase 3,Phase 2,Phase 1 174722-31-7 10201696
47
Miconazole Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1 22916-47-8 4189
48
Asparaginase Approved Phase 3,Phase 2,Phase 1 9015-68-3
49
Cytarabine Approved, Investigational Phase 3,Phase 2,Phase 1 147-94-4 6253
50
Daunorubicin Approved Phase 3,Phase 2,Phase 1 20830-81-3 30323

Interventional clinical trials:

(show top 50) (show all 390)

id Name Status NCT ID Phase Drugs
1 Pilot Study of Combination Therapy With CHOP-Zenapax (CHOP-daclizumab) Completed NCT01418430 Phase 4 CHOP-daclizumab
2 CEOP/IVE/GDP Compared With CEOP as the First-line Therapy for Newly Diagnosed Adult Patients With PTCL Recruiting NCT02533700 Phase 4 CEOP/IVE/GDP chemotherapy regimen;CEOP chemotherapy regimen for 6 cycles
3 MP Diagnostics HTLV Blot 2.4 Post-Market Clinical Study Active, not recruiting NCT03226119 Phase 4
4 Neurotoxicity of Spinal Anesthesia With Ropivacaine and Bupivacaine Not yet recruiting NCT03293472 Phase 4 Ropivacaine;Bupivacaine
5 Levofloxacin Compared With Cefepime in Treating Cancer Patients With Fever and Neutropenia Unknown status NCT00020865 Phase 3 cefepime hydrochloride;levofloxacin
6 Early Hospital Discharge or Standard Inpatient Care in Cancer Patients Receiving Antibiotics for Febrile Neutropenia Unknown status NCT00445497 Phase 3 amoxicillin-clavulanate potassium;ciprofloxacin
7 Ketamine Hydrochloride and Best Pain Management in Treating Cancer Patients With Neuropathic Pain Unknown status NCT01316744 Phase 3 ketamine hydrochloride
8 Combination Chemotherapy With or Without Rituximab in Treating Older Patients With Non-Hodgkin's Lymphoma Unknown status NCT00052936 Phase 3 CHOP regimen;cyclophosphamide;doxorubicin hydrochloride;prednisone;vincristine sulfate
9 A Study for Aggressive Adult T-cell Leukemia-lymphoma (ATLL) Completed NCT00145002 Phase 3 VCAP-AMP-VECP with G-CSF and intrathecal prophylaxis;biweekly-CHOP with G-CSF and intrathecal prophylaxis
10 Treatment of Acute Lymphoblastic Leukemia (ALL) in Younger Adults Completed NCT00327678 Phase 3 Rituximab;Imatinib Mesylate
11 Study of Treatment High Risk and/or Low Risk Acute Lymphoblastic leukémia(ALL) Adults Stage III Completed NCT00483132 Phase 3 interferon alpha 2a
12 ALL2008 Protocol for Childhood Acute Lymphoblastic Leukemia (ALL) - 6MP Consolidation Therapy Completed NCT00816049 Phase 3 6MPindividualized;6MPfixed
13 Prevention of Infection in Patients With Hematologic Cancer and Persistent Fever Caused by a Low White Blood Cell Count Completed NCT00003805 Phase 3 piperacillin sodium;piperacillin-tazobactam;tazobactam sodium;vancomycin
14 Radiation Therapy in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma Who Have Undergone Stem Cell Transplantation Completed NCT00031668 Phase 3
15 Darbepoetin Alfa With or Without Iron in Treating Anemia Caused By Chemotherapy in Patients With Cancer Completed NCT00661999 Phase 3 sodium ferric gluconate complex in sucrose
16 Dalteparin to Prevent Complications in Cancer Patients Receiving Chemotherapy Through a Catheter Completed NCT00006083 Phase 3 Fragmin
17 Personalized Information or Basic Information in Helping Patients Make Decisions About Participating in a Clinical Trial Completed NCT00750009 Phase 3
18 American Ginseng in Treating Patients With Fatigue Caused by Cancer Completed NCT00719563 Phase 3 American ginseng
19 Darbepoetin Alfa Compared With Epoetin Alfa in Treating Anemia in Patients Receiving Chemotherapy for Cancer Completed NCT00070382 Phase 3 darbepoetin alfa;epoetin alfa
20 Opioid Titration Order Sheet or Standard Care in Treating Patients With Cancer Pain Completed NCT00666211 Phase 3
21 St. John's Wort in Relieving Fatigue in Patients Undergoing Chemotherapy or Hormone Therapy for Cancer Completed NCT00005805 Phase 3
22 Levofloxacin to Prevent Infection Following Chemotherapy in Treating Patients With Solid Tumors or Lymphoma Completed NCT00005590 Phase 3 levofloxacin
23 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
24 Liposomal Amphotericin B in Treating Granulocytopenia and Persistent Unexplained Fever in Cancer Patients Completed NCT00003938 Phase 3 liposomal amphotericin B
25 Caspofungin Acetate Compared With Amphotericin B Liposomal in Treating Patients With Persistent Fever and Neutropenia Following Cancer Treatment Completed NCT00008359 Phase 3 caspofungin acetate;liposomal amphotericin B
26 Treatment for Chronic Pain in Patients With Advanced Cancer Completed NCT00003687 Phase 3 dextromethorphan hydrobromide;morphine sulfate
27 Ondansetron in Treating Patients With Advanced Cancer and Chronic Nausea and Vomiting Not Caused by Cancer Treatment Completed NCT00006348 Phase 3 ondansetron
28 Optimization of Therapy in Adult Patients With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma by Individualised, Targeted and Intensified Treatment Recruiting NCT02881086 Phase 3 Rituximab;Nelarabine;PEG-Asparaginase;Imatinib;Idarubicin;Dexamethasone;Cyclophosphamide;Fludarabine;Vincristine;Mercaptopurine;VP16;Daunorubicin (DNR);Methotrexate;Cytarabine;Vindesine;Adriamycin;Prednisolone
29 Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma Recruiting NCT02112916 Phase 3 Bortezomib;Cyclophosphamide;Cytarabine;Daunorubicin Hydrochloride;Dexamethasone;Doxorubicin Hydrochloride;Etoposide;Hydrocortisone Sodium Succinate;Ifosfamide;Leucovorin Calcium;Mercaptopurine;Methotrexate;Pegaspargase;Thioguanine;Vincristine Sulfate
30 Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma Recruiting NCT03117751 Phase 2, Phase 3 Prednisone;Vincristine;Daunorubicin;Pegaspargase;Erwinase®;Rituximab;Cyclophosphamide;Cytarabine;Mercaptopurine;Dasatinib;Methotrexate;Blinatumomab;Ruxolitinib;Bortezomib;Dexamethasone;Doxorubicin;Etoposide;Clofarabine;Vorinostat;Idarubicin
31 Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Children and Adolescents Recruiting NCT03020030 Phase 3 Pegaspargase;Erwinia asparaginase;Cyclophosphamide;CYTARABINE;DASATINIB;DEXAMETHASONE;Dexrazoxane;Doxorubicin;ETOPOSIDE;HYDROCORTISONE;LEUCOVORIN CALCIUM;MERCAPTOPURINE;METHOTREXATE;NELARABINE;Vincristine
32 Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma Active, not recruiting NCT00408005 Phase 3 Asparaginase;Cyclophosphamide;Cytarabine;Daunorubicin Hydrochloride;Dexamethasone;Doxorubicin Hydrochloride;Leucovorin Calcium;Mercaptopurine;Methotrexate;Nelarabine;Pegaspargase;Prednisone;Thioguanine;Vincristine Sulfate
33 International Collaborative Treatment Protocol For Children And Adolescents With Acute Lymphoblastic Leukemia Active, not recruiting NCT01117441 Phase 3 PEG-L-asparaginase;cyclophosphamide;cytarabine;daunorubicin hydrochloride;dexamethasone;doxorubicin hydrochloride;etoposide;ifosfamide;mercaptopurine;methotrexate;prednisone;thioguanine;vincristine sulfate;vindesine;daunoxome;fludarabine
34 Combination Chemotherapy and Donor Stem Cell Transplant in Treating Patients With Aplastic Anemia or Hematologic Cancer Active, not recruiting NCT00003816 Phase 2, Phase 3 busulfan;carboplatin;cyclophosphamide;etoposide;fludarabine phosphate;melphalan;thiotepa
35 Combination Chemotherapy With or Without Etoposide in Treating Older Patients With Non-Hodgkin's Lymphoma Terminated NCT00060385 Phase 2, Phase 3 CHOP regimen;EPOCH regimen;cyclophosphamide;doxorubicin hydrochloride;etoposide;prednisone;vincristine sulfate
36 Trial to Assess Effect of Raltegravir on HTLV-1 Proviral Load Unknown status NCT01620736 Phase 2 Raltegravir
37 High-Dose Chemotherapy Given Together With Peripheral Blood Stem Cell Transplant in Treating Patients With Intestinal T-Cell Lymphoma Unknown status NCT00669812 Phase 2 carmustine;cyclophosphamide;cytarabine;doxorubicin hydrochloride;epirubicin hydrochloride;etoposide;ifosfamide;melphalan;methotrexate;prednisolone;vincristine sulfate
38 Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ Lymphomas Unknown status NCT01805037 Phase 1, Phase 2 brentuximab vedotin
39 Combination Chemotherapy Followed by Donor Bone Marrow Transplant or Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer or Genetic Disorders Unknown status NCT00008307 Phase 2 cyclosporine;fludarabine phosphate;melphalan;methylprednisolone;mycophenolate mofetil
40 Alemtuzumab and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV T-Cell Non-Hodgkin's Lymphoma Unknown status NCT00363090 Phase 1, Phase 2 cyclophosphamide;doxorubicin hydrochloride;prednisone;vincristine sulfate
41 Arsenic Trioxide in Treating Patients With Recurrent or Refractory Acute Leukemia, Chronic Myeloide Leukemia, Myelodysplasia, Lymphoma, or Myeloma Unknown status NCT00003885 Phase 2 arsenic trioxide
42 Stem Cell Transplant in Treating Patients With Hematological Cancer or Other Disorders Unknown status NCT00740467 Phase 2 busulfan;cyclophosphamide;cyclosporine;fludarabine phosphate;mycophenolate mofetil
43 Vaccine Therapy and GM-CSF in Treating Patients With CNS Lymphoma Unknown status NCT00621036 Phase 2 methotrexate;thiotepa
44 External-Beam Radiation Therapy With or Without Indinavir and Ritonavir in Treating Patients With Brain Metastases Unknown status NCT00637637 Phase 2 indinavir sulfate;ritonavir
45 Combination Chemotherapy in Treating Adults With Acute Lymphocytic Leukemia Unknown status NCT00002531 Phase 2 asparaginase;cyclophosphamide;cytarabine;daunorubicin hydrochloride;dexamethasone;doxorubicin hydrochloride;etoposide;ifosfamide;leucovorin calcium;mercaptopurine;methotrexate;mitoxantrone hydrochloride;prednisolone;teniposide;thioguanine;vincristine sulfate;vindesine
46 Combination Chemotherapy in Treating Adult Patients With Newly Diagnosed Acute Lymphoblastic Leukemia Unknown status NCT01005758 Phase 2 cyclophosphamide;cytarabine;dexamethasone;doxorubicin hydrochloride;etoposide phosphate;hydrocortisone sodium succinate;imatinib mesylate;mercaptopurine;methotrexate;methylprednisolone;pegaspargase;prednisolone;prednisone;vincristine sulfate
47 Safety and Immunogenicity of Recombinant WT1 Antigen-Specific Cancer Immunotherapeutic Combined With Infusion of Treg Depleted T Cells for Adult WT1 Acute Myeloid Leukemia Unknown status NCT01513109 Phase 1, Phase 2
48 Lenalidomide in HTLV-1 Adult T-Cell Leukemia Completed NCT01274533 Phase 2 Lenalidomide
49 Phase II Study of KW-0761 in Subjects With CCR4-positive Adult T-cell Leukemia-lymphoma Completed NCT00920790 Phase 2
50 Campath-1H for Treating Adult T-Cell Leukemia/Lymphoma Completed NCT00061048 Phase 2

Search NIH Clinical Center for Adult T-Cell Leukemia

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Adult T-Cell Leukemia cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Adult T-Cell Leukemia:
Hematopoietic stem cells for treatment of hematologic malignancies
Embryonic/Adult Cultured Cells Related to Adult T-Cell Leukemia:
Bone marrow-derived hematopoietic stem cells

Cochrane evidence based reviews: leukemia-lymphoma, adult t-cell

Genetic Tests for Adult T-Cell Leukemia

Anatomical Context for Adult T-Cell Leukemia

MalaCards organs/tissues related to Adult T-Cell Leukemia:

39
T Cells, Bone, Bone Marrow, Skin, Liver, Thyroid, Myeloid

Publications for Adult T-Cell Leukemia

Articles related to Adult T-Cell Leukemia:

(show top 50) (show all 866)
id Title Authors Year
1
Detection of human T-cell lymphotropic virus type I-specific cytotoxic T-cells may predict treatment responses in adult T-cell leukemia/lymphoma patients. ( 28656327 )
2017
2
Galectin-9 as a Predictive Marker for the Onset of Immune-Related Adverse Effects Associated with Anti-CCR4 MoAb Therapy in Patients with Adult T Cell Leukemia. ( 28321034 )
2017
3
Welder's pulmonary hemosiderosis associated with systemic iron overload following exacerbation of acute adult T-cell leukemia/lymphoma. ( 28883221 )
2017
4
A Unique T-Cell Receptor Amino Acid Sequence Selected by Human T-Cell Lymphotropic Virus Type 1 Tax301-309-Specific Cytotoxic T Cells in HLA-A24:02-Positive Asymptomatic Carriers and Adult T-Cell Leukemia/Lymphoma Patients. ( 28724766 )
2017
5
Generalized rash and lymphocytosis as clinical onset adult T-cell leukemia/lymphoma. ( 28645687 )
2017
6
Hypersensitivity reaction to I^-lactam antibiotics in patients with adult T-cell leukemia/lymphoma treated with mogamulizumaba8c. ( 28793956 )
2017
7
Monitoring molecular response in adult T-cell leukemia by high-throughput sequencing analysis of HTLV-1 clonality. ( 28811663 )
2017
8
Therapy-related Acute Myeloid Leukemia after the Long-term Administration of Low-dose Etoposide for Chronic-type Adult T-cell Leukemia-lymphoma: A Case Report and Literature Review. ( 28717086 )
2017
9
Dismal outcome of allogeneic hematopoietic stem cell transplantation for relapsed adult T-cell leukemia/lymphoma, a Japanese nation-wide study. ( 28067877 )
2017
10
Mogamulizumab for relapsed adult T-cell leukemia-lymphoma: Updated follow-up analysis of phase I and II studies. ( 28776876 )
2017
11
Epidemiological and clinical features of adult T-cell leukemia-lymphoma in Japan, 2010-2011: A nationwide survey. ( 28905463 )
2017
12
Genetic alterations in adult T-cell leukemia/lymphoma. ( 28627735 )
2017
13
Crucial role of carbonic anhydrase IX in tumorigenicity of xenotransplanted adult T-cell leukemia-derived cells. ( 28075522 )
2017
14
Human T-cell leukemia virus type I Tax genotype analysis in Okinawa, the southernmost and remotest islands of Japan: Different distributions compared with mainland Japan and the potential value for the prognosis of aggressive adult T-cell leukemia/lymphoma. ( 28866351 )
2017
15
Early Onset of HTLV-1 Associated Myelopathy/Tropical Spastic Paraparesis (HAM/TSP) and Adult T-cell Leukemia/Lymphoma (ATL): Systematic Search and Review. ( 28582585 )
2017
16
Mogamulizumab for the treatment of relapsed or refractory adult T-cell leukemia-lymphoma. ( 28756726 )
2017
17
Cyclin-dependent kinase 9 is a novel specific molecular target in adult T-cell leukemia/lymphoma. ( 28646117 )
2017
18
Hematopoeitic stem cell transplantation for adult T cell leukemia-lymphoma: Who is the best candidate? ( 27786571 )
2017
19
Adult T-cell leukemia cell-induced uveitis: rapid increase in adult T-cell leukemia cells disrupts the blood-ocular barrier. ( 28677112 )
2017
20
Evaluation of INOS, ICAM-1, and VCAM-1 gene expression: A study of adult T cell leukemia malignancy associated with HTLV-1. ( 28110427 )
2017
21
Anti-laminin-332-type mucous membrane pemphigoid in a patient with adult T-cell leukemia/lymphoma and graft-versus-host disease. ( 28771781 )
2017
22
Adult T cell leukemia aggressivenness correlates with loss of both 5-hydroxymethylcytosine and TET2 expression. ( 28881727 )
2017
23
Choices and Challenges in the Treatment of Adult T-Cell Leukemia/Lymphoma. ( 28796965 )
2017
24
Acute myelitis resembling human T-lymphotropic virus type 1-associated myelopathy presenting as high-signal-intensity long cord lesions on T2-weighted magnetic resonance images combined with lymphoma-type adult T-cell leukemia/lymphoma. ( 27817856 )
2017
25
Detection of Tax-specific CTLs in lymph nodes of adult T-cell leukemia/lymphoma patients and its association with Foxp3 positivity of regulatory T-cell function. ( 28599462 )
2017
26
Adult T-Cell Leukemia/Lymphoma. ( 28796966 )
2017
27
Expression and significance of Pim-3 kinase in adult T-cell leukemia. ( 28833639 )
2017
28
Development of a complete human IgG monoclonal antibody to transferrin receptor 1 targeted for adult T-cell leukemia/lymphoma. ( 28189691 )
2017
29
Efficiency of AUY922 in mice with adult T-cell leukemia/lymphoma. ( 27347156 )
2016
30
T Cell Receptor VI^ Staining Identifies the Malignant Clone in Adult T cell Leukemia and Reveals Killing of Leukemia Cells by Autologous CD8+ T cells. ( 27893842 )
2016
31
Adult T-Cell Leukemia/Lymphoma: Rarely Encountered in the United States. ( 27521318 )
2016
32
Adult T-cell leukemia/lymphoma in donor cells responding to second allogeneic hematopoietic stem cell transplantation using unrelated cord blood: the Nagasaki Transplant Group experience. ( 27210445 )
2016
33
Restoration of microRNA-212 causes a G0/G1 cell cycle arrest and apoptosis in adult T-cell leukemia/lymphoma cells by repressing CCND3 expression. ( 27493231 )
2016
34
Cytological diagnosis of adult T-cell leukemia/lymphoma in sputum. ( 26972585 )
2016
35
Prolonged lymphocytosis as the first manifestation of Hodgkin-like adult T-cell leukemia/lymphoma. ( 27789281 )
2016
36
Genetic landscape of adult T-cell leukemia/lymphoma. ( 27169444 )
2016
37
The relation between clinical features of adult T-cell leukemia/lymphoma and the serum levels of soluble CD25 and CD30. ( 27498727 )
2016
38
TIM-3 expression in lymphoma cells predicts chemoresistance in patients with adult T-cell leukemia/lymphoma. ( 27446463 )
2016
39
Early leukemic transformation of adult T-cell leukemia/lymphoma presenting as meningeal lymphoma. ( 27862199 )
2016
40
Characterization of patients with aggressive adult T-cell leukemia-lymphoma in Okinawa, Japan: a retrospective analysis of a large cohort. ( 27329124 )
2016
41
Xenotransplantation elicits salient tumorigenicity of adult T-cell leukemia-derived cells via aberrant AKT activation. ( 26928911 )
2016
42
Multicenter Phase II Study of Lenalidomide in Relapsed or Recurrent Adult T-Cell Leukemia/Lymphoma: ATLL-002. ( 27621400 )
2016
43
Two cases of primary adult T-cell leukemia/lymphoma of bone: case reports and a review of the literature. ( 27145781 )
2016
44
Lenalidomide in Adult T-Cell Leukemia/Lymphoma. ( 27863193 )
2016
45
Dysregulation of c-Myb Pathway by Aberrant Expression of Proto-oncogene MYB Provides the Basis for Malignancy in Adult T-cell Leukemia/lymphoma Cells. ( 27307595 )
2016
46
Alopecia areata, thyroiditis and vitiligo vulgaris in a Japanese patient with smoldering type adult T-cell leukemia/lymphoma. ( 27651025 )
2016
47
PD-L1 expression on neoplastic or stromal cells is respectively a poor or good prognostic factor for adult T-cell leukemia/lymphoma. ( 27418641 )
2016
48
Pretransplantation Anti-CCR4 Antibody Mogamulizumab Against Adult T-Cell Leukemia/Lymphoma Is Associated With Significantly Increased Risks of Severe and Corticosteroid-Refractory Graft-Versus-Host Disease, Nonrelapse Mortality, and Overall Mortality. ( 27507878 )
2016
49
Phase II study of alemtuzumab (CAMPATH-1Ar) in patients with HTLV-1-associated adult T-cell leukemia/lymphoma. ( 27486175 )
2016
50
Tax fingerprint in adult T-cell leukemia. ( 27056993 )
2016

Variations for Adult T-Cell Leukemia

Expression for Adult T-Cell Leukemia

Search GEO for disease gene expression data for Adult T-Cell Leukemia.

Pathways for Adult T-Cell Leukemia

Pathways related to Adult T-Cell Leukemia according to GeneCards Suite gene sharing:

(show all 29)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
13.73 BCL2L1 CCND2 CDKN2A FAS IL2 IL2RA
2
Show member pathways
12.74 BCL2L1 CDKN2A FAS PMAIP1 TP53
3
Show member pathways
12.71 CCND2 FAS IL2 IL2RA TP53
4 12.58 BCL2L1 CCND2 FAS IL2 IL2RA TP53
5 12.38 BCL11B FAS FOXP3 IL2 IL2RA TXN
6
Show member pathways
12.36 BCL2L1 IL2 IL2RA TP53
7 12.25 BCL2L1 CCND2 CDKN2A IL2 IL2RA TP53
8
Show member pathways
12.24 CCND2 CDKN2A FAS PMAIP1 TP53
9 12.2 CCND2 CDKN2A PMAIP1 TP53
10 12.14 BCL11B BCL2L1 CCND2 TP53
11 12.14 BCL2L1 FAS PMAIP1 TXN
12
Show member pathways
12.1 BCL2L1 CCND2 IL2 IL2RA
13 11.86 CCND2 CDKN2A PMAIP1 TP53
14
Show member pathways
11.73 BCL2L1 FAS PMAIP1
15 11.7 CCND2 PMAIP1 TP53
16 11.69 CD7 IL2 IL2RA
17
Show member pathways
11.66 FOXP3 IL2 IL2RA
18 11.66 BCL2L1 JUND TP53 TXN
19 11.56 BCL2L1 CCND2 CDKN2A FAS PMAIP1 TP53
20 11.52 BCL2L1 CDKN2A FAS PMAIP1 TP53
21 11.4 FOXP3 IL2 IL2RA
22
Show member pathways
11.38 BCL2L1 CCND2 FOXP3 IL2 IL2RA
23 11.36 FAS JUND TP53
24
Show member pathways
11.33 BCL2L1 FAS PMAIP1
25 11.25 BCL2L1 PMAIP1 TP53
26
Show member pathways
11.22 FAS FOXP3 IL2 IL2RA
27
Show member pathways
10.98 CDKN2A PMAIP1 TP53
28 10.73 BCL2L1 CDKN2A FAS IL2 TP53
29 10.71 BCL2L1 TP53

GO Terms for Adult T-Cell Leukemia

Biological processes related to Adult T-Cell Leukemia according to GeneCards Suite gene sharing:

(show all 24)
id Name GO ID Score Top Affiliating Genes
1 immune response GO:0006955 9.97 CD7 FAS IL2 IL2RA TNFRSF8
2 negative regulation of apoptotic process GO:0043066 9.95 BCL11B BCL2L1 CCND2 FAS IL2 TP53
3 apoptotic process GO:0006915 9.87 BCL2L1 CADM1 CDKN2A FAS IL2RA PMAIP1
4 negative regulation of cell proliferation GO:0008285 9.85 BCL11B CDKN2A FOXP3 PTHLH TNFRSF8 TP53
5 negative regulation of inflammatory response GO:0050728 9.77 FOXP3 IL2 IL2RA
6 activation of cysteine-type endopeptidase activity involved in apoptotic process GO:0006919 9.74 CDKN2A FAS PMAIP1
7 positive regulation of apoptotic process GO:0043065 9.73 BCL2L1 CDKN2A FAS PMAIP1 TNFRSF8 TP53
8 response to radiation GO:0009314 9.67 BCL2L1 JUND TXN
9 extrinsic apoptotic signaling pathway in absence of ligand GO:0097192 9.63 BCL2L1 FAS IL2
10 positive regulation of protein oligomerization GO:0032461 9.62 PMAIP1 TP53
11 negative regulation of immune response GO:0050777 9.61 FOXP3 IL2RA
12 positive regulation of intrinsic apoptotic signaling pathway GO:2001244 9.61 BCL2L1 PMAIP1 TP53
13 replicative senescence GO:0090399 9.59 CDKN2A TP53
14 hepatocyte apoptotic process GO:0097284 9.58 BCL2L1 FAS
15 positive regulation of regulatory T cell differentiation GO:0045591 9.56 FOXP3 IL2
16 activation-induced cell death of T cells GO:0006924 9.52 FAS IL2RA
17 negative regulation of T-helper 17 cell differentiation GO:2000320 9.51 FOXP3 IL2
18 regulation of T cell homeostatic proliferation GO:0046013 9.4 IL2 IL2RA
19 regulation of mitochondrial membrane permeability GO:0046902 9.33 BCL2L1 PMAIP1 TP53
20 negative regulation of lymphocyte proliferation GO:0050672 9.13 FOXP3 IL2 IL2RA
21 T cell homeostasis GO:0043029 8.92 FAS FOXP3 IL2RA PMAIP1
22 positive regulation of transcription from RNA polymerase II promoter GO:0045944 10.08 BCL11B CDKN2A EPC1 FOXP3 IL2 JUND
23 negative regulation of transcription from RNA polymerase II promoter GO:0000122 10.02 EPC1 FOXP3 JUND PRDM16 TP53 TXN
24 negative regulation of transcription, DNA-templated GO:0045892 10 CDKN2A EPC1 FOXP3 PRDM16 TP53

Sources for Adult T-Cell Leukemia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....